CelLBxHealth plc (CLBX) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Dec 2025 05:51 PM
RNS
PDMR Dealing and ESOT Share Purchase
15 Dec 2025 02:41 PM
RNS
Results of General Meeting and Board Changes
02 Dec 2025 11:11 AM
RNS
Additional Subscription
01 Dec 2025 05:44 PM
RNS
Result of Retail Offer
25 Nov 2025 05:40 PM
RNS
Update to Admission of Fundraising Shares
25 Nov 2025 08:00 AM
RNS
Launch of Retail Offer
25 Nov 2025 07:55 AM
RNS
Result of Oversubscribed Placing and Subscription
24 Nov 2025 06:32 PM
RNS
Proposed Placing and Subscription
18 Nov 2025 07:00 AM
RNS
QIAGEN Collaboration and Co-Marketing Agreement
05 Nov 2025 06:16 PM
RNS
Further Update on Funding
05 Nov 2025 07:00 AM
RNS
CelLBxHealth Presents Proof-of-Concept Study
04 Nov 2025 07:00 AM
RNS
Expert Consensus on CTCs; Update on Funding
29 Oct 2025 07:00 AM
RNS
CHANGE OF NAME
16 Oct 2025 07:00 AM
RNS
Appointments: Interim CEO and senior board advisor
08 Oct 2025 07:00 AM
RNS
Strategy Update
29 Sep 2025 07:00 AM
RNS
Presentation of Data on Glioblastoma
12 Sep 2025 07:00 AM
RNS
Board Changes
09 Sep 2025 07:01 AM
RNS
Interim Results
09 Sep 2025 07:00 AM
RNS
Change of Adviser
05 Sep 2025 02:58 PM
RNS
Notice of Results
20 Aug 2025 07:00 AM
RNS
ANGLE announces collaboration with Myriad Genetics
08 Jul 2025 07:00 AM
RNS
PARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30 Jun 2025 05:50 PM
RNS
Result of 2025 Annual General Meeting
17 Jun 2025 07:00 AM
RNS
EACR 2025: Innovation in AR expression profiling
17 Jun 2025 07:00 AM
RNS
EACR 2025: Data demonstrating DNA dual analysis
10 Jun 2025 07:00 AM
RNS
Novel discoveries into the biology of cancer
09 Jun 2025 07:00 AM
RNS
POSTING OF ANNUAL REPORT AND NOTICE OF AGM
06 Jun 2025 07:00 AM
RNS
Board Changes
28 May 2025 07:00 AM
RNS
Preliminary Results
23 May 2025 07:00 AM
RNS
Notice of Results
28 Apr 2025 07:00 AM
RNS
RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21 Mar 2025 07:00 AM
RNS
Issue of LTIP Options and Share Options
21 Mar 2025 07:00 AM
RNS
Results of Eisai Phase 2 pilot study
06 Feb 2025 07:00 AM
RNS
Novel findings using Parsortix
29 Jan 2025 07:00 AM
RNS
Analysis of CTC-DNA and ctDNA using Illumina assay
24 Jan 2025 10:05 AM
RNS
Parsortix used in research paper from ETH Zurich
23 Jan 2025 07:00 AM
RNS
Trading Update
13 Dec 2024 08:43 AM
RNS
HER2 presentation at SABCS
15 Nov 2024 07:00 AM
RNS
Parsortix based PD-L1 assay showcased at AACR
15 Nov 2024 07:00 AM
RNS
Research on HER2 assay kit showcased at AACR
13 Nov 2024 07:00 AM
RNS
ANGLE presents two posters at EACR
11 Nov 2024 07:00 AM
RNS
Parsortix enriched CTC & ctDNA in NSCLC patients
17 Oct 2024 07:00 AM
RNS
Publication demonstrates CTC profiling potential
26 Sep 2024 07:01 AM
RNS
100th publication supporting Parsortix system use
26 Sep 2024 07:00 AM
RNS
Half-year Report
23 Sep 2024 07:00 AM
RNS
Exclusive agreement for DNA NGS panel
19 Sep 2024 07:00 AM
RNS
Agreement with Recursion Pharmaceuticals
17 Sep 2024 07:00 AM
RNS
Notice of Interim Results and Webcast
22 Aug 2024 07:00 AM
RNS
Data supporting FDA approval published in Journal
01 Aug 2024 07:00 AM
RNS
Independent Parsortix study

ANGLE PLC is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. The Company's product includes Parsortix cell separation system.

Founded in 1994, AGL share price listed on LSE in 2004 under the ticker AGL.

UK 100

Latest directors dealings